flutamide has been researched along with Breast Neoplasms in 40 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiandrogen flutamide has been reported to exert antiproliferative actions on breast cancer both in vitro and in vivo." | 7.69 | Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. ( Boccuzzi, G; Brignardello, E; Di Monaco, M; Gatto, V; Leonardi, L, 1995) |
| "The estrogen-sensitive human breast cancer cell line ZR-75-1 was used to study the regulation of 17 beta-hydroxysteroid dehydrogenase (17 beta HSD), the enzyme responsible for the interconversion of estrone (E1) and estradiol (E2)." | 7.68 | Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. ( Couture, P; Labrie, F; Simard, J; Thériault, C, 1993) |
| "The purpose of our study was to evaluate the effects of 5 alpha-dihydrotestosterone (DHT) and hydroxyflutamide (HF), alone or in combination, on androgen receptor (AR) dynamics and on cellular growth in cultured breast cancer cells (EVSA-T)." | 7.68 | Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). ( Bernasconi, D; Cassulo, S; Fazzuoli, L; Giordano, G; Marugo, M; Miglietta, L; Ravera, F, 1992) |
| "Hormonal changes induced by the pure antiandrogen flutamide were studied in three postmenopausal metastatic breast cancer patients." | 7.67 | Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. ( Ballerini, P; Fariselli, G; Recchione, C; Secreto, G; Zambetti, M, 1988) |
| "Ten men with advanced breast cancer were evaluated for response to treatment with the luteinizing hormone-releasing hormone (LH-RH) analogue, buserelin, alone or in combination with the antiandrogen, flutamide." | 7.67 | Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. ( Doberauer, C; Niederle, N; Schmidt, CG, 1988) |
| "The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer." | 7.67 | Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988) |
| "The antiandrogen flutamide has been reported to exert antiproliferative actions on breast cancer both in vitro and in vivo." | 3.69 | Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells. ( Boccuzzi, G; Brignardello, E; Di Monaco, M; Gatto, V; Leonardi, L, 1995) |
| "The estrogen-sensitive human breast cancer cell line ZR-75-1 was used to study the regulation of 17 beta-hydroxysteroid dehydrogenase (17 beta HSD), the enzyme responsible for the interconversion of estrone (E1) and estradiol (E2)." | 3.68 | Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. ( Couture, P; Labrie, F; Simard, J; Thériault, C, 1993) |
| "The effects of estradiol (E2), dihydrotestosterone (DHT) and dehydro-3-epiandrosterone (DHEA) on proliferation and progesterone receptor induction were studied in a breast cancer cell line (T47D) expressing estrogen, androgen, and progesterone receptors." | 3.68 | Effects of androgens on proliferation and progesterone receptor levels in T47D human breast cancer cells. ( Brentani, MM; Liberato, MH; Sonohara, S, 1993) |
| "The purpose of our study was to evaluate the effects of 5 alpha-dihydrotestosterone (DHT) and hydroxyflutamide (HF), alone or in combination, on androgen receptor (AR) dynamics and on cellular growth in cultured breast cancer cells (EVSA-T)." | 3.68 | Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). ( Bernasconi, D; Cassulo, S; Fazzuoli, L; Giordano, G; Marugo, M; Miglietta, L; Ravera, F, 1992) |
| "Using electron microscopy, in the human breast cancer cell line T47D, the synthetic progestin R5020, and 5 alpha-dihydrotestosterone were shown to increase significantly the number of lipid droplets per cell section compared to control cells or estradiol- and dexamethasone-treated cells." | 3.67 | Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. ( Chalbos, D; Chambon, M; Rochefort, H; Vial, HJ, 1989) |
| "Hormonal changes induced by the pure antiandrogen flutamide were studied in three postmenopausal metastatic breast cancer patients." | 3.67 | Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. ( Ballerini, P; Fariselli, G; Recchione, C; Secreto, G; Zambetti, M, 1988) |
| "Ten men with advanced breast cancer were evaluated for response to treatment with the luteinizing hormone-releasing hormone (LH-RH) analogue, buserelin, alone or in combination with the antiandrogen, flutamide." | 3.67 | Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. ( Doberauer, C; Niederle, N; Schmidt, CG, 1988) |
| "The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer." | 3.67 | Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988) |
| "This study describes the inhibitory effect of 5 alpha-dihydrotestosterone (5 alpha-DHT) and its precursors testosterone (T) and androst-4-ene-3,17-dione (delta 4-DIONE) on the growth of the estrogen-sensitive human breast cancer cell line ZR-75-1." | 3.67 | Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. ( Baker, D; Labrie, F; Poulin, R, 1988) |
| "The erythema is an effect of radiotherapy treatment in breast cancer patients." | 2.73 | Comparison of three instrumental methods for the objective evaluation of radiotherapy induced erythema in breast cancer patients and a study of the effect of skin lotions. ( Franzén, L; Geladi, P; Larson, J; Lindholm-Sethson, B; Nyström, J; Svensk, AC, 2007) |
| "Prostate cancer is the most common cancer diagnosed in men." | 1.37 | The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. ( Dotan, N; Mahajna, J; Wasser, SP, 2011) |
| "Estrogen receptor-negative (ER-) breast cancer is a heterogeneous disease with limited therapeutic options." | 1.37 | Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. ( Chia, KM; Liu, J; Naderi, A, 2011) |
| "Molecular apocrine breast cancer is an estrogen receptor negative subtype characterized by the over-expression of steroid response genes." | 1.36 | Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. ( Liu, J; Naderi, A, 2010) |
| "Studies of the role of androgens on breast cancer development are controversial and the mechanisms involved are not fully understood." | 1.35 | Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. ( Davis, FB; Davis, PJ; Lin, C; Lin, HY; London, D; Shih, A; Sun, M; Tang, HY, 2009) |
| "The inhibitory action of 17alpha-AED on human mammary carcinomas appears to be independent of either the alpha estrogen or the androgen receptors." | 1.31 | 17 alpha androstenediol inhibition of breast tumor cell proliferation in estrogen receptor-positive and -negative cell lines. ( Carter, WH; Huynh, PN; Loria, RM, 2000) |
| "Tamoxifen was also effective in blocking the formation of pituitary adenoma in the sex hormone treated rats." | 1.31 | The effect of flutamide and tamoxifen on sex hormone-induced mammary carcinogenesis and pituitary adenoma. ( Leung, G; Tsao, SW; Wong, YC, 2002) |
| "Using cultured human PMC42 breast cancer cells, we have determined effects of the androgen R1881 on the activity of the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 kinase." | 1.30 | Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. ( Funder, JW; Li, H; Liu, JP; Zhu, X, 1999) |
| "We report that growth of LNCaP human prostate cancer cells is significantly stimulated (up to 120% above control) by physiological estradiol (E2) concentrations." | 1.29 | Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. ( Calabrò, M; Carruba, G; Castagnetta, LA; Farruggio, R; Miceli, MD; Oliveri, G; Pfeffer, U; Sorci, CM, 1995) |
| "Although the majority of primary human breast cancers express the androgen receptor (AR), the role of androgens in breast cancer growth and progression is poorly understood." | 1.29 | Androgens induce divergent proliferative responses in human breast cancer cell lines. ( Bentel, JM; Birrell, SN; Hickey, TE; Horsfall, DJ; Ricciardelli, C; Tilley, WD; Weger, MA, 1995) |
| "The human mammary cancer cell line MFM-223, which contains only androgen receptors, was used as a model to investigate androgen receptor mediated effects of these antiprogestins." | 1.29 | Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. ( Beck, S; Hackenberg, R; Hannig, K; Schmidt-Rhode, P; Scholz, A; Schulz, KD, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (22.50) | 18.7374 |
| 1990's | 21 (52.50) | 18.2507 |
| 2000's | 6 (15.00) | 29.6817 |
| 2010's | 4 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caceres, S | 1 |
| Monsalve, B | 1 |
| Peña, L | 1 |
| de Andres, PJ | 1 |
| Alonso-Diez, A | 1 |
| Illera, MJ | 1 |
| Woodward, WA | 1 |
| Reuben, JM | 1 |
| Silvan, G | 1 |
| Illera, JC | 1 |
| Lin, HY | 1 |
| Sun, M | 1 |
| Lin, C | 1 |
| Tang, HY | 1 |
| London, D | 1 |
| Shih, A | 1 |
| Davis, FB | 1 |
| Davis, PJ | 1 |
| Naderi, A | 2 |
| Liu, J | 2 |
| Dotan, N | 1 |
| Wasser, SP | 1 |
| Mahajna, J | 1 |
| Chia, KM | 1 |
| Khalkhali-Ellis, Z | 1 |
| Christian, AL | 1 |
| Kirschmann, DA | 1 |
| Edwards, EM | 1 |
| Rezaie-Thompson, M | 1 |
| Vasef, MA | 1 |
| Gruman, LM | 1 |
| Seftor, RE | 1 |
| Norwood, LE | 1 |
| Hendrix, MJ | 1 |
| Nyström, J | 1 |
| Svensk, AC | 1 |
| Lindholm-Sethson, B | 1 |
| Geladi, P | 1 |
| Larson, J | 1 |
| Franzén, L | 1 |
| Di Monaco, M | 2 |
| Brignardello, E | 2 |
| Leonardi, L | 2 |
| Gatto, V | 2 |
| Boccuzzi, G | 2 |
| Castagnetta, LA | 1 |
| Miceli, MD | 1 |
| Sorci, CM | 1 |
| Pfeffer, U | 1 |
| Farruggio, R | 1 |
| Oliveri, G | 1 |
| Calabrò, M | 1 |
| Carruba, G | 1 |
| Birrell, SN | 1 |
| Bentel, JM | 1 |
| Hickey, TE | 1 |
| Ricciardelli, C | 1 |
| Weger, MA | 1 |
| Horsfall, DJ | 1 |
| Tilley, WD | 1 |
| Pizzini, A | 1 |
| Gallo, M | 1 |
| Couture, P | 1 |
| Thériault, C | 1 |
| Simard, J | 4 |
| Labrie, F | 6 |
| Escaleira, MT | 1 |
| Sonohara, S | 2 |
| Brentani, MM | 2 |
| Liberato, MH | 1 |
| Hackenberg, R | 3 |
| Hannig, K | 1 |
| Beck, S | 1 |
| Schmidt-Rhode, P | 1 |
| Scholz, A | 1 |
| Schulz, KD | 3 |
| Szelei, J | 1 |
| Jimenez, J | 1 |
| Soto, AM | 1 |
| Luizzi, MF | 1 |
| Sonnenschein, C | 1 |
| Werner, A | 1 |
| Aichberger, A | 1 |
| Krebs, D | 1 |
| Singh, SM | 1 |
| Markiewicz, L | 1 |
| Gurpide, E | 1 |
| Lapointe, J | 1 |
| Fournier, A | 1 |
| Richard, V | 1 |
| Labrie, C | 1 |
| Loos, S | 1 |
| Zhu, X | 1 |
| Li, H | 1 |
| Liu, JP | 1 |
| Funder, JW | 1 |
| Huynh, PN | 1 |
| Carter, WH | 1 |
| Loria, RM | 1 |
| Mercader, M | 1 |
| Bodner, BK | 1 |
| Moser, MT | 1 |
| Kwon, PS | 1 |
| Park, ES | 1 |
| Manecke, RG | 1 |
| Ellis, TM | 1 |
| Wojcik, EM | 1 |
| Yang, D | 1 |
| Flanigan, RC | 1 |
| Waters, WB | 1 |
| Kast, WM | 1 |
| Kwon, ED | 1 |
| Leung, G | 1 |
| Tsao, SW | 1 |
| Wong, YC | 1 |
| Dreicer, R | 1 |
| Wilding, G | 1 |
| Hawighorst, T | 1 |
| Filmer, A | 1 |
| Slater, EP | 1 |
| Bock, K | 1 |
| Beato, M | 1 |
| Marugo, M | 1 |
| Bernasconi, D | 1 |
| Miglietta, L | 1 |
| Fazzuoli, L | 1 |
| Ravera, F | 1 |
| Cassulo, S | 1 |
| Giordano, G | 1 |
| Dauvois, S | 2 |
| Dumont, M | 1 |
| Haagensen, DE | 2 |
| Dupont, A | 1 |
| Bélanger, A | 1 |
| Lacourcière, Y | 1 |
| Béland, L | 1 |
| Cusan, L | 1 |
| Lachance, R | 1 |
| Lévesque, C | 1 |
| Mérand, Y | 1 |
| Namer, M | 1 |
| Chambon, M | 1 |
| Rochefort, H | 2 |
| Vial, HJ | 1 |
| Chalbos, D | 2 |
| Secreto, G | 1 |
| Recchione, C | 1 |
| Zambetti, M | 1 |
| Fariselli, G | 1 |
| Ballerini, P | 1 |
| Canellos, GP | 1 |
| Doberauer, C | 1 |
| Niederle, N | 1 |
| Schmidt, CG | 1 |
| Perrault, DJ | 1 |
| Logan, DM | 1 |
| Stewart, DJ | 1 |
| Bramwell, VH | 1 |
| Paterson, AH | 1 |
| Eisenhauer, EA | 1 |
| Poulin, R | 1 |
| Baker, D | 1 |
| Haagensen, D | 1 |
| Parish, T | 1 |
| Benz, C | 1 |
| Hollander, C | 1 |
| Miller, B | 1 |
2 reviews available for flutamide and Breast Neoplasms
| Article | Year |
|---|---|
Steroid hormone agonists and antagonists in the treatment of cancer.
Topics: Androgen Antagonists; Androgens; Breast Neoplasms; Epidermal Growth Factor; Estrogen Antagonists; Es | 1992 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
2 trials available for flutamide and Breast Neoplasms
| Article | Year |
|---|---|
Comparison of three instrumental methods for the objective evaluation of radiotherapy induced erythema in breast cancer patients and a study of the effect of skin lotions.
Topics: Aloe; Breast Neoplasms; Dose-Response Relationship, Radiation; Electrons; Erythema; Female; Flutamid | 2007 |
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
Topics: Androgen Antagonists; Antigen-Presenting Cells; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2001 |
36 other studies available for flutamide and Breast Neoplasms
| Article | Year |
|---|---|
In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines.
Topics: Androstenedione; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Dihyd | 2018 |
Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells.
Topics: Androgen Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; | 2009 |
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy P | 2010 |
The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androgens; Aniline Compounds; Breast Neoplasms | 2011 |
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Topics: Androgen Receptor Antagonists; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen.
Topics: Actins; Adult; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumo | 2004 |
Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dihydrotestosterone | 1995 |
Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor.
Topics: Androgen Antagonists; Base Sequence; Breast Neoplasms; Cell Division; Cell Line; Cell Nucleus; Cytos | 1995 |
Androgens induce divergent proliferative responses in human breast cancer cell lines.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Division; Dihydrotestosterone; Flut | 1995 |
5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol.
Topics: Androstenediol; Breast Neoplasms; Cell Division; Diethylstilbestrol; Dihydrotestosterone; Estradiol; | 1994 |
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Dexamethasone; Dihydrotestosterone; Estradiol; E | 1993 |
Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells.
Topics: Breast Neoplasms; Calcitriol; Dihydrotestosterone; Estradiol; Flutamide; Humans; Receptors, Androgen | 1993 |
Effects of androgens on proliferation and progesterone receptor levels in T47D human breast cancer cells.
Topics: Androgens; Breast Neoplasms; Cell Division; Dehydroepiandrosterone; Dihydrotestosterone; Down-Regula | 1993 |
Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Binding, Competitive; Breast Neoplasms; Cell Division; | 1996 |
Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor.
Topics: Androgen Antagonists; Androgens; Anilides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Div | 1997 |
[Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells?].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cell Line; C | 1996 |
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Topics: Androgen Antagonists; Anilides; Animals; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carri | 1997 |
Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays.
Topics: Adenocarcinoma; Alkaline Phosphatase; Androgen Antagonists; Androgens; Breast Neoplasms; Cyproterone | 1997 |
Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells.
Topics: Androgen Antagonists; Androgens; Breast Neoplasms; Caspase 3; Caspases; Dihydrotestosterone; Down-Re | 1999 |
Regulation of GCDFP-15 expression in human mammary cancer cells.
Topics: Androgen Antagonists; Anilides; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Protei | 1999 |
Androgen stimulates mitogen-activated protein kinase in human breast cancer cells.
Topics: Androgen Antagonists; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; DNA Replicatio | 1999 |
17 alpha androstenediol inhibition of breast tumor cell proliferation in estrogen receptor-positive and -negative cell lines.
Topics: Anabolic Agents; Androgen Antagonists; Androgen Receptor Antagonists; Androstenediol; Antineoplastic | 2000 |
The effect of flutamide and tamoxifen on sex hormone-induced mammary carcinogenesis and pituitary adenoma.
Topics: Animals; Anticarcinogenic Agents; Breast; Breast Neoplasms; Carcinogenicity Tests; Estradiol; Female | 2002 |
Regulation of androgen receptor mRNA and protein level by steroid hormones in human mammary cancer cells.
Topics: Blotting, Northern; Breast Neoplasms; Cyproterone; Dihydrotestosterone; Estradiol; Flutamide; Gene E | 1992 |
Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T).
Topics: Androgen Antagonists; Breast Neoplasms; Cell Division; Dihydrotestosterone; Flutamide; Humans; Recep | 1992 |
Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells.
Topics: Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Drug Interact | 1990 |
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1990 |
Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer.
Topics: Androgens; Apolipoproteins; Apolipoproteins D; Binding, Competitive; Biomarkers, Tumor; Breast Neopl | 1990 |
Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors.
Topics: Acetates; Breast Neoplasms; Dihydrotestosterone; Dose-Response Relationship, Drug; Fatty Acids; Flut | 1989 |
Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer.
Topics: Anilides; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestoster | 1988 |
Hormonal agents and treatment of cancer.
Topics: Androgens; Breast Neoplasms; Diethylstilbestrol; Dihydrotestosterone; Estrogens; Female; Flutamide; | 1986 |
Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Estradiol; Flutam | 1988 |
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Topics: Anilides; Breast Neoplasms; Canada; Drug Evaluation; Flutamide; Follow-Up Studies; Humans; Neoplasm | 1988 |
Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.
Topics: Androgen Antagonists; Androstenedione; Breast Neoplasms; Cell Division; Cell Line; Dihydrotestostero | 1988 |
Identification and androgen regulation of two proteins released by T47D human breast cancer cells.
Topics: Androgens; Antibodies, Monoclonal; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Pro | 1987 |
Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.
Topics: Aminoglutethimide; Animals; Azasteroids; Breast Neoplasms; Cell Cycle; Cell Line; Danazol; Dexametha | 1986 |